Indaptus Therapeutics, Inc. — Form 8-K
Filed September 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 22/100
What the filing says
Indaptus Therapeutics filed an 8-K on September 4, 2026 disclosing Item 5.02 events: departure of director(s) or officer(s) and/or election of directors and appointment of officer(s), along with compensatory arrangement changes. The filing provides no specific names, dollar amounts, dates of departure/appointment, share counts, or details of compensation modifications in the available text excerpt.
Why this rating
No substantive details disclosed in filing excerpt. Officer/director changes are routine corporate governance events; without specifics on who departed, who was appointed, or compensation terms, impact cannot be assessed. Boilerplate 8-K filing.
Extracted items
- 5.02 exec change
- 9.01 exhibits
See more from September 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.